Apotex Inc.’s Post

Reflecting on ESMO 2023, we at RAS have put together some of the important and very interesting research that was presented. Let us take a look back #esmo23 #oncology #competitiveintelligence #researchanddevelopment #cancercare #oncologyresearch #pharma

A Recap of ESMO 2023: Let's take a closer look at some of the notable and pioneering research unveiled during the ESMO conference held last month in Madrid, Spain. #esmo23 #raslss #oncology #oncologyresearch #competitiveintelligence #conferences #healthcare #rarediseases #cancerresearch #pharmaceutical #pharma

We attended the EMSO 2023 congress in Oct, at Madrid, during which we had the opportunity to learn about some of the recent advances in the field of cancer research, and also connect with some great minds! This year, >30,000 people attended the congress in person from >150 countries. Some of the "hot" topics that garnered a lot of attention were ADCs (antibody-drug conjugates) with several data readouts in late-breaking sessions such as 302/KEYNOTE-A39, TROPION-Breast01, DESTINY-PanTumor 01 etc. These molecules are anticipated to set new therapeutic standards. In addition to ADCs, lung cancer also took center stage during the conference with >25 sessions. Below is a crisp summary of the most notable topics that we captured during ESMO 2023 At RAS, we provide comprehensive conference coverage support across multiple therapeutic areas. If you would like to know more about our conference services or get hold of our conference reports, do reach out to us! Please like and share if you found the summary useful and comment below if you'd like us to send you a sample report. #oncology #cancerresearch #cancer #researchanddevelopment #conference #medicalconference #oncologyresearch #raslss #consultingservice #esmo2023 #esmo23

A recap from ESMO 2023 #esmo23 #raslss #oncology #oncologyresearch #competitiveintelligence #conferences #healthcare #rarediseases #cancerresearch #pharmaceutical #pharma

A recap of ESMO 2023: Let's revisit some of the significant and groundbreaking research presented at last month's ESMO conference in Madrid, Spain #esmo23 #raslss #oncology #oncologyresearch #competitiveintelligence #conferences #healthcare #rarediseases #cancerresearch #pharmaceutical #pharma

Thoughts on this? >> Merck KGaA's bet on head and neck cancer drug from Debiopharm ends in Phase 3 failure >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #healthcare #pharmaceutical #biotech #pharma

Ambrx’s ARX517 Shows Promising Efficacy And Safety In Advanced Prostate Cancer (ESMO 2023) #pharma #pharmaceutical #pharmtales #latestnews #pharmanews #pharmaceuticalindustry #ambrx #antibodydrugconjugates #prostatecancer https://lnkd.in/dpcDC4s6

🌟 Exciting News in Pharmaceutical and Biotech Innovations! 💪 Are you curious about the groundbreaking therapeutics that redefine druggability or the revolutionary combination of cancer vaccines and T-cell therapies? Look no further! Discover the inspiring journey of Prosion Therapeutics and ErVimmune. Learn how these innovative companies started and their remarkable contributions to the healthcare industry. To unlock the full story, click on the link below: 👉 https://bit.ly/3UPbvMg

🚨 Drug Discovery 2023: Track Insight 🚨 Zahra Jawad, CEO & Founder at CREASALLIS, will be talking about "Creating enhanced biotherapeutics for oncology" at #DrugDiscovery2023. A tumour is a difficult environment to access with any kind of therapeutic agent, even those that are targeted to the tumour specifically. Creasallis has found a way to improve access to tumours for antibody or protein derived compounds. Simply put, a normal protein or antibody drug may have the address of the tumour but the door is only open a little. Using the Creasallis technology, the door can be opened wide, allowing much more therapeutic agent to reach the tumour cells, improving efficacy and reducing side-effects. Join Zahra in Track 8 - Biopharmaceutical Discovery on Thursday 19th October to find out more. Register your free ticket now 👉https://lnkd.in/eMx5qHbx #DD23 #ELRIG

Thoughts on this? >> Merck KGaA's bet on head and neck cancer drug from Debiopharm ends in Phase 3 failure >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #healthcare #pharma #biotech #pharmaceutical